Sinoway Industrial Co., Ltd.

Entecavir Intermediate Entecavir Intermediate

Entecavir Intermediate
Related Products
  • NanoActive alpha lipoic acid (ALA) 1077-28-7

    1.Basic information of NanoActive alpha lipoic acidProduct Name: NanoActive alpha lipoic acid (ALA)Other Names: NanoActive THIOOCTIC ACIDAppearance: yellow, viscous and transparent liquidTest Method: ...

  • NanoActive Astaxanthin 472-61-7

    1.Basic information of NanoActive AstaxanthinProduct Name: NanoActive AstaxanthinOther Names: NanoActive AstaAppearance: reddish to dark red, viscous and transparent liquidTest Method: HPLCCAS NO.: 47...

  • NanoActive Curcumin 458-37-7

    1.Basic information of NanoActive CurcuminProduct Name: NanoActive CurcuminOther Names: NanoActive turmeric extractAppearance: yellow, viscous and transparent liquidTest Method: HPLCCAS NO.: 458-37-7S...

Basic Information of Entecavir Intermediate

  • CAS No of key intermediates. 1354715-15-3
  • Other Names: CMBC
  • Purity: 97%up
  • Appearance: White or off-white powder
  • Single impurity 0.8%below
  • Total impurity 3%below

Usage of Entecavir Intermediate

  • Entecavir, indications for the product is suitable for active replication of the virus, serum aminotransferase ALT continued to rise or liver histology showed active disease in chronic adult hepatitis B treatment.
  • Nucleosides, when used alone or in combination with other antiretroviral drugs, have been reported to have lactic acidosis and severe fatty hepatomegaly, including deaths.
  • When patients with chronic hepatitis B stop anti-hepatitis B treatment, including entecavir, has been found to have reports of severe acute hepatitis attack. The liver function of patients who discontinue anti-hepatitis B treatment should be closely monitored from clinical and laboratory tests, and should be followed up for at least months. If necessary, resume treatment of hepatitis B virus.

MORE_DETAIL Entecavir Intermediate

Basic Information of Entecavir Intermediate

  • CAS No of key intermediates. 1354715-15-3
  • Other Names: CMBC
  • Purity: 97%up
  • Appearance: White or off-white powder
  • Single impurity 0.8%below
  • Total impurity 3%below

Usage of Entecavir Intermediate

  • Entecavir, indications for the product is suitable for active replication of the virus, serum aminotransferase ALT continued to rise or liver histology showed active disease in chronic adult hepatitis B treatment.
  • Nucleosides, when used alone or in combination with other antiretroviral drugs, have been reported to have lactic acidosis and severe fatty hepatomegaly, including deaths.
  • When patients with chronic hepatitis B stop anti-hepatitis B treatment, including entecavir, has been found to have reports of severe acute hepatitis attack. The liver function of patients who discontinue anti-hepatitis B treatment should be closely monitored from clinical and laboratory tests, and should be followed up for at least months. If necessary, resume treatment of hepatitis B virus.
Related Articles
Leave a Message Email Us

we will contact you within 24 hours.

  • TEL:+86-0592-5854962
  • FAX:+86-0592-5854960
  • EMAIL: xie@china-sinoway.com
  • ADDRESS:Floor 16, Huicheng Business Center, No. 839, Xiahe Rd., Siming Dist. Xiamen, Fujian, China
//